Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)

H. H. Yoon, J. C. Bendell, F. S. Braiteh, I. Firdaus, P. A. Philip, A. L. Cohn, N. Lewis, D. M. Anderson, E. Arrowsmith, J. D. Schwartz, L. Gao, Y. Hsu, Y. Xu, D. Ferry, S. R. Alberts, Z. A. Wainberg

Research output: Contribution to journalComment/debatepeer-review

Abstract

A sentence was omitted from the funding statement in the original article: 'Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number P30CA022453.' This has now been added to the online version of the article.

Original languageEnglish (US)
Pages (from-to)2016
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number12
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Corrigendum: Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: A randomized, double-blind, multicenter Phase II trial (Annals of Oncology (2016) 27 (2196-2203) DOI: 10.1093/annonc/mdw423)'. Together they form a unique fingerprint.

Cite this